Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > BUSINESS
BUSINESS
- Nippon Kayaku’s Novel DDS Formulation of Paclitaxel Disappoints in PIII for Breast Cancer
July 6, 2016
- Takeda Gains Rights to TiGenix’s Cx601 Stem Cell Treatment Outside US
July 6, 2016
- Delving into Securities Filings - 3: Six Companies Report Higher Pay, More Employees
July 6, 2016
- Delving into Securities Filings - 2: Average Annual Pay at 3 Generic Majors Tops 7 Mil. Yen
July 5, 2016
- Takeda Gets Option to Acquire US Developer of Gastroparesis Treatment
July 5, 2016
- Takeda Files for Japan Approval of MM Drug Ixazomib
July 5, 2016
- Belsomra Comes Back to Top Position in GP Market: Anterio
July 4, 2016
- Delving into Securities Filings - 1: 1st and 2nd-Tier Makers Continue to Shed Jobs as Generic Peers See Rise in Workforce
July 4, 2016
- Sanofi Japan Completes Merger of Genzyme Japan
July 4, 2016
- Eisai Gives Global R&D Updates on Dementia, Oncology
July 1, 2016
- Filing for 1st Japan-Made Nucleic Acid Expected by Year-End If PIII Yields Positive Data
July 1, 2016
- Toho Holdings Appoints Ex-Qol Exec Takada as Senior Executive Officer
July 1, 2016
- Nichi-Iko Aims for 20% Share of Generic Market in “80% Generic Era”: President
June 30, 2016
- Kyowa Kirin’s KRN23 Gets BT Designation for X-Linked Hypophosphatemia in Children
June 30, 2016
- Novel Anti-HIV Agent Genvoya to Hit Japan Market on July 8: JT, Torii
June 30, 2016
- Celgene Files Revlimid for ATL in Japan
June 30, 2016
- Reconsider Appropriate Diabetes Drug Combos Including GLP-1 Agents: Diabetologist
June 29, 2016
- MSD Initiates Long-Term Observational Study of Treatment with Oral Hypoglycemic Agents
June 29, 2016
- Boehringer-Sanofi Asset Swap Slated to Close by Year’s End; Fate of Japan Units Subject to Future Discussions
June 28, 2016
- Daiichi Sankyo, Servier Sign Sales Accord for Edoxaban in Canada
June 28, 2016
ページ
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…